deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT01946074

A Study of ABT-165 in Subjects With Solid Tumors

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors

Sponsor: AbbVie

Conditions Advanced Solid Tumors
Interventions ABBV-181 ABT-165 FOLFIRI paclitaxel
Updated 22 times since 2017 Last updated: Dec 13, 2023 Started: Aug 8, 2013 Primary completion: Sep 28, 2022 Completion: Sep 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumors, this trial is completed. The trial is conducted by AbbVie and has accumulated 22 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~May 2022 · 11 months · monthly snapshot~May 2022 – ~Nov 2022 · 6 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Jan 2024 · 9 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE1

  4. Apr 2023 — Jan 2024 [monthly]

    Completed PHASE1

  5. Jan 2023 — Apr 2023 [monthly]

    Completed PHASE1

▶ Show 17 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1

  2. Nov 2022 — Dec 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. May 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Jul 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

  9. Mar 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  10. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  11. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  13. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  14. Nov 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE1

  15. Aug 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  16. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations